checkAd
    Startseite > Aktien > InspireMD > Nachrichten
    InspireMD Aktie
    1,9500
     
    EUR
    +3,17 %
    +0,0600 EUR
    Letzter Kurs 03.05.24 Tradegate
    1,8700
     
    EUR
    803 STK
    Geldkurs 03.05.24
    2,0200
     
    EUR
    739 STK
    Briefkurs 03.05.24
    ISIN: US45779A8466 · WKN: A3CMP3 · SYM: II2 · USA

    Neueste Nachrichten

    InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
    03.04.24 · globenewswire · InspireMD
    InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
    26.03.24 · globenewswire · InspireMD
    InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
    06.03.24 · globenewswire · InspireMD
    InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
    28.02.24 · globenewswire · InspireMD
    InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard Neuroprotection System
    12.02.24 · globenewswire · InspireMD
    InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
    31.01.24 · globenewswire · InspireMD
    InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America
    03.01.24 · globenewswire · InspireMD
    InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard Neuroprotection System
    20.12.23 · globenewswire · InspireMD
    InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
    27.11.23 · globenewswire · InspireMD
    InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update
    06.11.23 · globenewswire · InspireMD
    InspireMD to Participate in Upcoming November Investor Conferences
    02.11.23 · globenewswire · InspireMD
    InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23
    01.11.23 · globenewswire · InspireMD